Vifor Pharma Deutschland GmbH Foreign Germany 100 % CSL Behring EPE Foreign Greece 100 % CSL Behring Asia Pacific Limited Foreign Hong Kong 100 % CSL Plasma Kft Foreign Hungary 100 % CSL Behring Kft. Foreign Hungary 100 % CSL Behring Ltd Foreign Israel 100 % CSL Behring SpA Foreign Italy 100 % Seqirus S.r.l Foreign Italy 100 % Vifor Pharma Italia S.r.l. Foreign Italy 100 % CSL Behring KK Foreign Japan 100 % CSL Korea Ltd Foreign Korea 100 % Seqirus Korea Limited Foreign Korea 100 % CSL Behring SDN. BHD. Foreign Malaysia 100 % CSL Behring SA de CV Foreign Mexico 100 % CSL Behring BV Foreign Netherlands 100 % Seqirus Netherlands B.V. Foreign Netherlands 100 % Vifor Pharma Nederland B.V. Foreign Netherlands 100 % CSL Behring (NZ) Limited Foreign New Zealand 100 % Seqirus (NZ) Limited Foreign New Zealand 100 % CSL Behring Panama S.A. Foreign Panama 100 % CSL Behring sp. z o.o. Foreign Poland 100 % CSL Behring, Unipessoal, Lda Foreign Portugal 100 % Vifor Pharma Portugal, S.A. Foreign Portugal 100 % Vifor Pharma Romania S.R.L. Foreign Romania 100 % Vifor Pharma RUS Limited Liability Company Foreign Russia 100 % CSL Behring Pte. Ltd. Foreign Singapore 100 % Seqirus Pte. Ltd. Foreign Singapore 100 % Vifor Pharma Asia Pacific Pte. Ltd. Foreign Singapore 100 % CSL Behring Slovakia sro Foreign Slovakia 100 % CSL Behring, S.A. Foreign Spain 100 % Seqirus Spain, S.L. Foreign Spain 100 % Vifor Pharma España, S.L. Foreign Spain 100 % Sanifit Therapeutics, S.A.3 Foreign Spain 100 % CSL Behring AB Foreign Sweden 100 % Vifor Pharma Nordiska AB Foreign Sweden 100 % Iscotec AB Foreign Sweden 100 % CSL Behring AG Foreign Switzerland 100 % CSL Behring Biotherapies GmbH Foreign Switzerland 100 % CSL Behring Lengnau AG Foreign Switzerland 100 % Seqirus AG Foreign Switzerland 100 % Vifor (International) AG Foreign Switzerland 100 % Vifor Pharma Management AG Foreign Switzerland 100 % Vifor Pharma Participations AG Foreign Switzerland 100 % Vifor Pharma Switzerland SA Foreign Switzerland 100 % CSL Behring Limited Foreign Taiwan 100 % CSL Behring Biyoterapi llac Dis Ticaret AS Foreign Turkey 100 % CSL Behring UK Limited Foreign UK 100 % Entity name (all represent body corporate entities unless otherwise specified) Australian or Foreign resident Country of Incorporation and Tax Residency1 Percentage owned (%) Consolidated Entity Disclosure Statement 2 For the Year Ended 30 June 2025 3 The liquidation of Sanifit Therapeutics, S.A. was registered with the Spanish Commercial Registry effective 4 June 2025. 131 CSL Limited Annual Report 2024/25
RkJQdWJsaXNoZXIy MjE2NDg3